Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Germline TERT promoter mutations are rare in familial melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. High accuracy of family history of melanoma in Danish melanoma cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Molecular subtype classification of urothelial carcinoma in Lynch syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Determinants of variable resource use for multidisciplinary team meetings in cancer care

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prevalence of cervical, oral, and anal human papillomavirus infection in women living with HIV in Denmark - The SHADE cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Benefits, barriers and opinions on multidisciplinary team meetings: a survey in Swedish cancer care

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Founder mutations with a large impact in distinct populations have been described in Lynch syndrome. In Denmark, the MLH1 c.1667+2_1667_+8TAAATCAdelinsATTT mutation accounts for 25 % of the MLH1 mutant families. We used the national Danish hereditary nonpolyposis colorectal cancer register to estimate the cumulative lifetime risks for Lynch syndrome-associated cancer in 16 founder mutation families with comparison to 47 other MLH1 mutant families. The founder mutation conferred comparable risks for colorectal cancer (relative risks, RR, of 0.99 for males and 0.79 for females) and lower risks for extracolonic cancer (RR of 0.69 for endometrial cancer and 0.39 for all other extracolonic cancers). We also characterized expression of key Wnt-signaling proteins in colorectal cancers with the founder mutation. Aberrant staining affected β-catenin in 59 %, E-cadherin in 68 %, TCF-4 in 94 % and Cyclin D1 in 68 % with extensive inter-tumor variability despite the same underlying germline mutation. In conclusion, the Danish MLH1 founder mutation that accounts for a significant proportion of Lynch syndrome and is associated with a lower risk for extracolonic cancers.
Original languageEnglish
JournalFamilial Cancer
Volume11
Issue number4
Pages (from-to)579-85
Number of pages7
ISSN1389-9600
DOIs
StatePublished - 2012

ID: 36470383